WO2007038720A3 - Modulation of tlr-mediated immune responses using adaptor oligonucleotides - Google Patents

Modulation of tlr-mediated immune responses using adaptor oligonucleotides Download PDF

Info

Publication number
WO2007038720A3
WO2007038720A3 PCT/US2006/037987 US2006037987W WO2007038720A3 WO 2007038720 A3 WO2007038720 A3 WO 2007038720A3 US 2006037987 W US2006037987 W US 2006037987W WO 2007038720 A3 WO2007038720 A3 WO 2007038720A3
Authority
WO
WIPO (PCT)
Prior art keywords
tlr
modulation
immune responses
mediated immune
adaptor oligonucleotides
Prior art date
Application number
PCT/US2006/037987
Other languages
French (fr)
Other versions
WO2007038720A2 (en
Inventor
Marion Jurk
Joerg Vollmer
Arthur M Krieg
Eugen Uhlmann
Bernhard O Noll
Original Assignee
Coley Pharm Gmbh
Coley Pharm Group Inc
Marion Jurk
Joerg Vollmer
Arthur M Krieg
Eugen Uhlmann
Bernhard O Noll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Gmbh, Coley Pharm Group Inc, Marion Jurk, Joerg Vollmer, Arthur M Krieg, Eugen Uhlmann, Bernhard O Noll filed Critical Coley Pharm Gmbh
Priority to CA002623764A priority Critical patent/CA2623764A1/en
Priority to BRPI0616770-5A priority patent/BRPI0616770A2/en
Priority to EP06836152A priority patent/EP1928500A2/en
Priority to AU2006294528A priority patent/AU2006294528A1/en
Priority to EA200800943A priority patent/EA200800943A1/en
Priority to JP2008533635A priority patent/JP2009510096A/en
Publication of WO2007038720A2 publication Critical patent/WO2007038720A2/en
Publication of WO2007038720A3 publication Critical patent/WO2007038720A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the ability of certain oligonucleotides to modify the profile of TLR ligands such as TLR7, TLR8 and TLR9 ligands.
PCT/US2006/037987 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides WO2007038720A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002623764A CA2623764A1 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides
BRPI0616770-5A BRPI0616770A2 (en) 2005-09-27 2006-09-27 modulation of tlr-mediated immune responses employing adapter oligonucleotides
EP06836152A EP1928500A2 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides
AU2006294528A AU2006294528A1 (en) 2005-09-27 2006-09-27 Modulation of TLR-mediated immune responses using adaptor oligonucleotides
EA200800943A EA200800943A1 (en) 2005-09-27 2006-09-27 MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS
JP2008533635A JP2009510096A (en) 2005-09-27 2006-09-27 Modulation of TLR-mediated immune responses using adapter oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72098105P 2005-09-27 2005-09-27
US60/720,981 2005-09-27

Publications (2)

Publication Number Publication Date
WO2007038720A2 WO2007038720A2 (en) 2007-04-05
WO2007038720A3 true WO2007038720A3 (en) 2007-06-21

Family

ID=37900484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037987 WO2007038720A2 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides

Country Status (9)

Country Link
EP (1) EP1928500A2 (en)
JP (1) JP2009510096A (en)
KR (1) KR20080059595A (en)
CN (1) CN101340931A (en)
AU (1) AU2006294528A1 (en)
BR (1) BRPI0616770A2 (en)
CA (1) CA2623764A1 (en)
EA (1) EA200800943A1 (en)
WO (1) WO2007038720A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2272069T3 (en) 1998-05-22 2007-04-16 Ottawa Health Research Institute METHODS AND PRODUCTS TO INDUCE IMMUNITY IN MUCOSAS.
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
MXPA05004588A (en) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection.
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
JP2009504803A (en) 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア TLR agonist
WO2007047396A2 (en) 2005-10-12 2007-04-26 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
CN101790380B (en) * 2007-02-07 2013-07-10 加利福尼亚大学董事会 Conjugates of synthetic TLR agonists and uses therefor
EP2207787B1 (en) * 2007-11-06 2014-11-12 AdiuTide Pharmaceuticals GmbH Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MX2011003625A (en) 2008-10-06 2011-05-31 Idera Pharmaceuticals Inc Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto.
BRPI1008383A2 (en) 2009-02-11 2016-02-23 Univ California compound, pharmaceutical composition, method for preventing, inhibiting or treating a condition, and use of a compound
JP6275380B2 (en) * 2009-06-01 2018-02-07 イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Enhancement of autoimmune and inflammatory disease treatment by immunoregulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9
NZ603155A (en) 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US11504425B2 (en) 2019-02-26 2022-11-22 Wayne State University Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers
CN114588130B (en) * 2020-11-20 2023-07-04 四川好医生攀西药业有限责任公司 Adhesive bandage containing periplaneta americana active ingredient and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
US20050054590A1 (en) * 2003-09-05 2005-03-10 Averett Devron R. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
WO2005025614A2 (en) * 2003-09-15 2005-03-24 Glaxo Group Limited Improvements in vaccination
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
US20050054590A1 (en) * 2003-09-05 2005-03-10 Averett Devron R. Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
WO2005025583A2 (en) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
WO2005025614A2 (en) * 2003-09-15 2005-03-24 Glaxo Group Limited Improvements in vaccination
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AKIRA S: "Mammalian Toll-like receptors", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 15, no. 1, February 2003 (2003-02-01), pages 5 - 11, XP004399365, ISSN: 0952-7915 *
CHUANG T-H ET AL: "CLONING AND CHARACTERIZATION OF A SUB-FAMILY OF HUMAN TOLL-LIKE RECEPTORS: HTLR7, HTLR8 AND HTLR9", CHEMISCHE TECHNIK, LEIPZIG, DE, vol. 11, no. 3, September 2000 (2000-09-01), pages 372 - 378, XP009000971 *
DU X ET AL: "THREE NOVEL MAMMALIAN TOLL-LIKE RECEPTORS: GENE STRUCTURE, EXPRESSION, AND EVOLUTION", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTEXT LTD., MONTROUGE, FR, vol. 11, no. 3, September 2000 (2000-09-01), pages 362 - 371, XP009000972, ISSN: 1148-5493 *
JURK M ET AL: "HUMAN TLR7 OR TLR8 INDEPENDENTLY CONFER RESPONSIVENESS TO THE ANTIVIRAL COMPOUND R-848", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 3, no. 6, June 2002 (2002-06-01), pages 499, XP009000821, ISSN: 1529-2908 *
WAGNER H: "Toll meets bacterial CpG-DNA", IMMUNITY, CELL PRESS, US, vol. 14, no. 5, May 2001 (2001-05-01), pages 499 - 502, XP002250852, ISSN: 1074-7613 *
WEERATNA ET AL: "TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 45, 1 November 2005 (2005-11-01), pages 5263 - 5270, XP005115867, ISSN: 0264-410X *
WIEGEL B J ET AL: "CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomysarcoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 8, 2003, pages 3105 - 3114, XP002990544, ISSN: 1078-0432 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration

Also Published As

Publication number Publication date
AU2006294528A1 (en) 2007-04-05
JP2009510096A (en) 2009-03-12
KR20080059595A (en) 2008-06-30
BRPI0616770A2 (en) 2011-06-28
CN101340931A (en) 2009-01-07
CA2623764A1 (en) 2007-04-05
WO2007038720A2 (en) 2007-04-05
EA200800943A1 (en) 2008-12-30
EP1928500A2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2007038720A3 (en) Modulation of tlr-mediated immune responses using adaptor oligonucleotides
WO2006116458A3 (en) Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2007042554A3 (en) Methods and compositions for treating immune disorders
IL186928A0 (en) Polar lipids mixture, their preparation and uses
WO2006050477A3 (en) Anti-microbial compositions and methods of making and using the same
WO2007024612A3 (en) 8-substituted benzoazepines as toll-like receptor modulators
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2010054154A3 (en) Bifidobacteria crispr sequences
WO2006091915A3 (en) Immunostimulatory oligonucleotides
WO2007064857A8 (en) Amphoteric liposome formulation
TWI318030B (en) Universal crimping connector
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2008142509A3 (en) Class a oligonucleotides with immunostimulatory potency
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
WO2010062396A3 (en) Virus like particle compositions and methods of use
HK1103391A1 (en) Cationic lipids and methods of use
WO2009018431A3 (en) Novel synthetic agonists of tlr9
WO2006122156A3 (en) Compounds for modulating trpv3 function
HK1124437A1 (en) Push-pull-coaxial plug connector
WO2007040840A3 (en) Aminodiazepines as toll-like receptor modulators
EP1939252A4 (en) Aqueous polytetrafluoroethylene dispersion and product made from same
WO2008033432A3 (en) Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
WO2008060626A3 (en) Compounds for modulating trpv3 function
WO2004080391A3 (en) Novel antibacterial agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680044386.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 190392

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2623764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004141

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008533635

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 566995

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006836152

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2856/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006294528

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087009932

Country of ref document: KR

Ref document number: 200800943

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2006294528

Country of ref document: AU

Date of ref document: 20060927

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06836152

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0616770

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080327